A common prostate cancer mutation retargets an epigenetic complex to force prostate cells down a malignant path, creating a possible therapeutic opportunity in the process.
More powerful than previous methods, a new approach for tagging and harvesting DNA-associated proteins from cells could open deeper insights into transcription control.
In a #WhyIScience Q&A, research associate Annie Apffel, from the Broad’s Proteomics Platform, explains her work in “interactomics” and talks about the value of mentors to emerging scientists
Similar mutations in the gene SPOP have completely opposite effects in prostate versus endometrial cancers. What does that mean for efforts aimed at functionally interpreting cancer genetic findings?